Real-world utilization, safety, and observed clinical outcomes of dapagliflozin among Sudanese patients with heart failure: a multicenter retrospective cohort study. Download PDF Abstract Dapagliflozin, a sodium–glucose cotransporter-2 (SGLT2) inhibitor, provides glycemic control and has proven cardiovascular and renal benefits in large trials, but its real-world use in Sudan has not been described. This study aimed to describe clinical characteristics, safety, adherence, and outcomes among Sudanese patients prescribed dapagliflozin in routine care.
A multicenter retrospective cohort study (April–July 2022) was conducted at three cardiac hospitals in Khartoum, Sudan. Adults ( n = 238) prescribed dapagliflozin for heart failure (HF) were enrolled. Data were obtained from medical records and structured patient interviews, capturing sociodemographic data, adverse events, adherence, hospitalizations, and deaths.
96.3% of patients received dapagliflozin at a starting dose of 10 mg once daily. Common adverse events were polyuria (65.1%) and urinary tract infection (32.8%). Following dapagliflozin therapy, mean LVEF increased from baseline to follow-up by 5.98 ± 7.39% points among 213 patients with paired LVEF data (paired p < 0.001), whereas HbA1c showed a reduction of 0.91 ± 1.78% points among 158 patients with paired HbA1c data (paired p < 0.001).
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with qualified healthcare professionals for medical decisions and treatment options.
Discover more from ChuckysCarnage
Subscribe to get the latest posts sent to your email.
